A cost–utility analysis of atezolizumab in the second-line treatment of patients with metastatic bladder cancer

摘要

Despite initial promising results, the IMvigor211 clinical trial failed to demonstrate an overall survival ( ) benefit for atezolizumab compared with chemotherapy as second-line treatment for metastatic bladder cancer (m ). However, given lessened adverse events ( s) and preserved quality of life ( ) with atezolizumab, there might still be investment value. To evaluate that potential value, we conducted a cost–utility analysis ( ) of atezolizumab compared with chemotherapy from the perspective of the Canadian health care payer.